# US 2024/0156944 A1 · Attenuated reovirus-based vaccine composition and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0156944 A1
- Document ID: US20240156944A1
- Status: Published application
- Kind: A1
- Application number: 18/283,363
- Filed: 2022-03-22
- Published: 2024-05-16
- Earliest claimed: 2021-03-23
- Assignees: Virocure, Inc.
- Applicants: Virocure, Inc.
- Inventors: Haeng Jun YOO; Tommy Michel ALAIN; Sang Kyoung HAN; Xiao XIANG; So Young KIM; Yeon Sook LEE; Ki Hoon SONG
- Web page: https://patentgrep.com/patent/US20240156944A1

## CPC

- A61K 39/12: Viral antigens
- A61K 39/15: Reoviridae, e.g. calf diarrhea virus
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61P 31/14: for RNA viruses
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- C12N 15/86: Viral vectors
- A61K 2039/5254: {avirulent or attenuated}
- C12N 2720/12022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2720/12034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to an attenuated reovirus-based vaccine composition and a use thereof, the attenuated reovirus, according to the present invention, having the 251st to 455th amino acids of a sigma-1 protein of a capsid truncated such that when an epitope of an antigenic protein inducing cancer or infectious disease is introduced to the truncated site of the sigma-1 protein, the epitope of the antigenic protein is stably expressed in a cell, and thus the effect is gained of exhibiting an immune response such as producing a neutralizing antibody or inducing cell-mediated immunity. As such, the present invention is expected to be usefully employable as a vaccine composition for cancer or infectious disease by introducing the epitope of the antigenic protein to the truncated site of the sigma-1 protein of the attenuated reovirus according to the present invention.

## Claims

### Claim 1

A polypeptide comprising an amino acid sequence of an attenuated reovirus sigma-1 protein; and an amino acid sequence of an epitope of an antigen causing cancer or an infectious disease, wherein the polypeptide comprises the 1 to 250th amino acid sequence of the attenuated reovirus sigma-1 protein truncated at the 251st amino acid position from the N-terminus; and
an amino acid sequence of an epitope of an antigen causing cancer or an infectious disease inserted at the amino acid position including and subsequent to the 251st from the N-terminus of the amino acid sequence of the attenuated reovirus sigma-1 protein.

### Claim 2 (depends on 1)

The polypeptide of claim 1, wherein the attenuated reovirus sigma-1 protein is represented by the amino acid sequence of SEQ ID NO: 1.

### Claim 3 (depends on 2)

The polypeptide of claim 2, wherein the attenuated reovirus sigma-1 protein is encoded by a base sequence represented by SEQ ID NO: 2.

### Claim 4 (depends on 1)

The polypeptide of claim 1, wherein the epitope forms or constitutes a fusion protein at the carboxy-terminus of the attenuated reovirus sigma-1 protein.

### Claim 5 (depends on 1)

The polypeptide of claim 1, further comprising one or more amino acid sequence selected from the group consisting of a linker (SEQ ID NO: 11), Myc protein (SEQ ID NO: 12), FLAG protein (SEQ ID NO: 13), and 2A peptide, both before and after the amino acid sequence of the epitope.

### Claim 6 (depends on 1)

The polypeptide of claim 1, wherein the cancer is one or more selected from the group consisting of liver cancer, glioma, sarcoma, colon cancer, breast cancer, prostate cancer, melanoma, lung cancer, head and neck cancer, ovarian cancer, bladder cancer, stomach cancer, esophageal cancer, bile duct cancer, pancreatic cancer, cervical cancer, skin cancer, lymphoma, thyroid cancer, bone marrow cancer, endometrial cancer, kidney cancer, rectal cancer, and brain tumor.

### Claim 7 (depends on 1)

The polypeptide of claim 1, wherein the infectious disease is one or more selected from the group consisting of coronavirus disease-19 (COVID-19), hepatitis C, influenza, human immunodeficiency virus (HIV)-induced acquired immune deficiency syndrome (AIDS), tuberculosis, severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), infantile enteritis caused by rotavirus, and non-bacterial acute gastroenteritis caused by norovirus.

### Claim 8 (depends on 1)

The polypeptide of claim 1, wherein the amino acid sequence of the epitope is one or more selected from the group consisting of SEQ ID NO: 3 to 10.

### Claim 9 (depends on 1)

The polypeptide of claim 1, wherein the base sequence encoding the epitope is substituted or inserted at positions 763 to 1416 of from the 5′ end of the base sequence encoding the attenuated reovirus sigma-1 protein.

### Claim 10 (depends on 1)

The polypeptide of claim 1, wherein the epitope induces an immune response by producing neutralizing antibodies or inducing cell-mediated immunity in a host.

### Claim 11 (depends on 1)

The polypeptide of claim 1, wherein the epitope is selected from the group consisting of CD4+ T cell, CD8+ T cell, and B-cell epitopes.

### Claim 12 (depends on 1)

A virus vector based on attenuated reovirus, comprising a polynucleotide encoding the polypeptide of claim 1 any-one-of-Glaims-1-to-14.

### Claim 13 (depends on 1)

A vaccine composition based on attenuated reovirus, comprising as an active ingredient, the polypeptide of claim 1, a polynucleotide encoding the same, or a virus vector comprising the polynucleotide encoding the same.

### Claim 14 (depends on 13)

The vaccine composition of claim 13, wherein the vaccine composition is for preventing or treating cancer or an infectious disease.

### Claim 15

A method of preparing a vaccine composition based on the attenuated reovirus, comprising the following steps:
a) preparing a reverse genetics virus vector comprising a base sequence encoding an attenuated reovirus sigma-1 protein represented by SEQ ID NO: 1; and
b) introducing a polynucleotide into the vector, wherein the polynucleotide encodes an attenuated reovirus sigma-1 protein and an epitope of an antigen causing cancer or an infectious disease, which is expressed as a fusion, by substituting or inserting a base at positions 763 to 1416 of the base sequence encoding the sigma-1 protein, so as to comprise a base sequence encoding the epitope of the antigen causing cancer or an infectious disease.

### Claim 16 (depends on 15)

The method of claim 15, further comprising the step of
c) producing and proliferating the vector based on the attenuated reovirus comprising the polynucleotide from the step b) in one or more cell selected from the group consisting of BHK21, L929, HEK293, CHO, PER.C6, HeLa, and Vero cells.

### Claim 17 (depends on 13)

A method for preventing or treating cancer or an infectious disease, comprising the step of administering the vaccine composition of claim 13 to a subject in need thereof.

### Claim 18

(canceled)

### Claim 19

(canceled)
